Theratechnologies (THTX) Competitors $1.67 -0.19 (-10.22%) Closing price 04:00 PM EasternExtended Trading$1.59 -0.08 (-4.79%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock THTX vs. CMPS, SEPN, CADL, DSGN, AVIR, ZYBT, CRVS, MBX, IMMP, and PRMEShould you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include COMPASS Pathways (CMPS), Septerna (SEPN), Candel Therapeutics (CADL), Design Therapeutics (DSGN), Atea Pharmaceuticals (AVIR), Zhengye Biotechnology (ZYBT), Corvus Pharmaceuticals (CRVS), MBX Biosciences (MBX), Immutep (IMMP), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry. Theratechnologies vs. COMPASS Pathways Septerna Candel Therapeutics Design Therapeutics Atea Pharmaceuticals Zhengye Biotechnology Corvus Pharmaceuticals MBX Biosciences Immutep Prime Medicine Theratechnologies (NASDAQ:THTX) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations and profitability. Do analysts rate THTX or CMPS? COMPASS Pathways has a consensus target price of $21.83, suggesting a potential upside of 606.58%. Given COMPASS Pathways' higher possible upside, analysts plainly believe COMPASS Pathways is more favorable than Theratechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theratechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00COMPASS Pathways 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in THTX or CMPS? 46.2% of COMPASS Pathways shares are owned by institutional investors. 4.3% of COMPASS Pathways shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, THTX or CMPS? Theratechnologies has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.29, suggesting that its share price is 129% more volatile than the S&P 500. Does the MarketBeat Community believe in THTX or CMPS? COMPASS Pathways received 35 more outperform votes than Theratechnologies when rated by MarketBeat users. Likewise, 81.25% of users gave COMPASS Pathways an outperform vote while only 53.57% of users gave Theratechnologies an outperform vote. CompanyUnderperformOutperformTheratechnologiesOutperform Votes3053.57% Underperform Votes2646.43% COMPASS PathwaysOutperform Votes6581.25% Underperform Votes1518.75% Does the media prefer THTX or CMPS? In the previous week, Theratechnologies had 5 more articles in the media than COMPASS Pathways. MarketBeat recorded 6 mentions for Theratechnologies and 1 mentions for COMPASS Pathways. COMPASS Pathways' average media sentiment score of 1.87 beat Theratechnologies' score of 0.92 indicating that COMPASS Pathways is being referred to more favorably in the news media. Company Overall Sentiment Theratechnologies Positive COMPASS Pathways Very Positive Is THTX or CMPS more profitable? COMPASS Pathways has a net margin of 0.00% compared to Theratechnologies' net margin of -3.75%. Theratechnologies' return on equity of 0.00% beat COMPASS Pathways' return on equity.Company Net Margins Return on Equity Return on Assets Theratechnologies-3.75% N/A -4.31% COMPASS Pathways N/A -63.85%-51.97% Which has higher earnings and valuation, THTX or CMPS? Theratechnologies has higher revenue and earnings than COMPASS Pathways. Theratechnologies is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheratechnologies$85.87M0.89-$23.96M-$0.18-9.28COMPASS PathwaysN/AN/A-$118.46M-$2.30-1.34 SummaryCOMPASS Pathways beats Theratechnologies on 10 of the 18 factors compared between the two stocks. Remove Ads Get Theratechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THTX vs. The Competition Export to ExcelMetricTheratechnologiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.71M$6.91B$5.63B$8.12BDividend YieldN/A2.73%4.56%4.01%P/E Ratio-16.907.2524.5119.05Price / Sales0.90224.46381.7992.83Price / CashN/A65.6738.1634.64Price / Book-3.756.496.934.35Net Income-$23.96M$142.41M$3.20B$247.23M7 Day Performance4.07%-2.75%-2.17%-0.43%1 Month Performance4.07%-4.44%3.14%-3.68%1 Year Performance15.48%-8.37%11.11%2.00% Theratechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THTXTheratechnologiesN/A$1.67-10.2%N/A+31.9%$76.79M$85.87M-16.70140Short Interest ↓News CoverageGap DownHigh Trading VolumeCMPSCOMPASS Pathways2.78 of 5 stars$3.11+0.3%$21.83+602.0%-68.0%$288.21MN/A-1.41120Positive NewsSEPNSepterna2.3875 of 5 stars$6.37+7.6%$34.00+433.8%N/A$282.85M$981,000.000.00N/AEarnings ReportCADLCandel Therapeutics2.7371 of 5 stars$8.66+7.4%$21.00+142.5%+400.0%$281.24M$120,000.00-5.0160DSGNDesign Therapeutics2.0128 of 5 stars$4.93+6.0%$8.00+62.3%+16.2%$279.84MN/A-5.8040Positive NewsAVIRAtea Pharmaceuticals2.6472 of 5 stars$3.20-0.6%$6.88+115.0%-15.6%$273.68MN/A-1.5570News CoverageZYBTZhengye BiotechnologyN/A$5.80+18.9%N/AN/A$273.56M$189.75M0.00278High Trading VolumeCRVSCorvus Pharmaceuticals2.3161 of 5 stars$4.25-1.4%$12.38+191.2%+90.3%$273.09MN/A-4.5730Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageMBXMBX Biosciences1.5348 of 5 stars$8.13+3.0%$37.25+358.2%N/A$271.74MN/A0.0036IMMPImmutep1.7705 of 5 stars$1.84-2.1%$8.50+362.0%-23.4%$267.83M$5.14M0.002,021PRMEPrime Medicine2.8637 of 5 stars$2.03+4.1%$13.38+558.9%-70.7%$266.26M$2.98M-0.99234 Remove Ads Related Companies and Tools Related Companies CMPS Competitors SEPN Competitors CADL Competitors DSGN Competitors AVIR Competitors ZYBT Competitors CRVS Competitors MBX Competitors IMMP Competitors PRME Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THTX) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theratechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
